

### Patient Information

YESCARTA® and TECARTUS™ can cause side effects that can lead to death.

Call or see your oncologist or get emergency help **RIGHT AWAY** if you have any of **these symptoms**:

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heartbeat
- Severe fatigue or weakness

YESCARTA, the YESCARTA Logo, TECARTUS, the TECARTUS Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc. © XXXX Kite Pharma, Inc. All Rights Reserved. | REMS CTF-0005 MMYYYY

Santa Monica, CA

### Important Information for Healthcare Providers

Name of treating oncologist:

Office phone:

After-hours phone:

Kite CAR T product administered:

YESCARTA®       TECARTUS™

Date of Kite CAR T infusion:

- This patient has received a CD19-

## Patient Wallet Card

**Carry this card with you at all times. SHOW THIS CARD if you go to the emergency room or see any physician.**

Tell any healthcare provider that sees you that you are being treated with YESCARTA® or TECARTUS™.

Stay within close proximity (within 2 hours) of the location where you received your treatment for at least 4 weeks after getting YESCARTA® or TECARTUS™.

directed genetically modified autologous T-cell immunotherapy (CAR T).

- CAR T therapy can cause cytokine release syndrome (CRS) and neurologic toxicities, which may be fatal or life threatening. CRS may involve any organ system



- Contact the patient's oncologist immediately for further information